TREATMENTS &
RESEARCH

Search the
latest
treatment
information
here.

Dr. Huntley's
Diagnosis
Checklist

Have a symptom?
See what questions
a doctor would ask.
 
Diseases » Septo-Optic Dysplasia » Treatments
 

Treatments for Septo-Optic Dysplasia

Treatments for Septo-Optic Dysplasia

The list of treatments mentioned in various sources for Septo-Optic Dysplasia includes the following list. Always seek professional medical advice about any treatment or change in treatment plans.

Septo-Optic Dysplasia: Marketplace Products, Discounts & Offers

Products, offers and promotion categories available for Septo-Optic Dysplasia:

Septo-Optic Dysplasia: Research Doctors & Specialists

Research all specialists including ratings, affiliations, and sanctions.

Discussion of treatments for Septo-Optic Dysplasia:

Treatment for SOD is symptomatic. Hormone deficiencies may be treated with hormone replacement therapy. The optical problems associated with SOD are generally not treatable. Vision, physical, and occupational therapies may be required. (Source: excerpt from NINDS Septo-Optic Dysplasia Information Page: NINDS)

Buy Products Related to Treatments for Septo-Optic Dysplasia

 
Shopping.com


Book Excerpts: Treatment of Septo-Optic Dysplasia

Treatments of Septo-Optic Dysplasia: Online Medical Books

16 MEDICAL BOOKS ONLINE! Review excerpts from medical books online, free, without registration, for more information about the treatments of Septo-Optic Dysplasia.

Hypopituitarism: Treatment
(Professional Guide to Diseases (Eighth Edition))

Replacement of hormones secreted by the target glands is the most effective treatment for hypopituitarism. Hormone replacement therapy includes cortisol, T4, and androgen or cyclic estrogen. Prolactin need not be replaced. The patient of reproductive age may benefit from administration of FSH and human chorionic gonadotropin to boost fertility. GH replacement is recommended for adults as well as children. Replacement is done by administering daily subcutaneous injections of one of two recombinant deoxyribonucleic acid (DNA) GHs, accompanied by follow-up of serum IGF-1 levels. Lean body mass increases, whereas adipose tissue — particularly in the abdomen — decreases. Risk of cardiovascular disease and osteoporosis also decrease with treatment. Many patients also notice an improved sense of well-being.

Somatrem, which is identical to hGH but is the product of recombinant DNA technology, has replaced GHs derived from human sources. It’s effective for treating dwarfism and stimulates growth increases as great as 4"to 6"(10 to 15 cm) in the first year of treatment. The growth rate tapers off in subsequent years. After pubertal changes have occurred, the effects of somatrem therapy are limited. Occasionally, a child becomes unresponsive to somatrem therapy, even with larger doses, perhaps because antibodies have formed against it. In such refractory patients, small doses of androgen may again stimulate growth but extreme caution is necessary to prevent premature closure of the epiphyses. Children with hypopituitarism may also need replacement of adrenal and thyroid hormones and, as they approach puberty, sex hormones.

» READ BOOK EXCERPT ONLINE »

Source: Professional Guide to Diseases (Eighth Edition), 2005

Hypopituitarism: Treatment
(Handbook of Diseases)

Replacement of hormones secreted by the target glands is the most effective treatment for hypopituitarism. Hormone replacement therapy includes cortisol, T4, and androgen or cyclic estrogen. Prolactin need not be replaced. The patient of reproductive age may benefit from cyclic administration of FSH and human chorionic gonadotropin to induce ovulation.

Clinical tip  In hypopituitarism, the TSH levels become an unreliable marker for thyroid hormone replacement. Therefore, follow free T4 levels in this patient.

Somatrem and others, identical to hGH but the product of recombinant deoxyribonucleic acid technology, have replaced growth hormones derived from human sources. They’re effective for treating dwarfism and stimulating growth increases as great as 6" (15.2 cm) in the first year of treatment. The growth rate tapers off in subsequent years. After pubertal changes have occurred, the effects of somatrem therapy are limited. Occasionally, a child becomes unresponsive to somatrem therapy, even with larger doses, perhaps because antibodies have formed against it. In such refractory patients, small doses of androgen may again stimulate growth, but extreme caution is necessary to prevent premature closure of the epiphyses. Children with hypopituitarism may also need replacement of adrenal and thyroid hormones and, as they approach puberty, sex hormones.

» READ BOOK EXCERPT ONLINE »

Source: Handbook of Diseases, 2003



 » Next page: Doctors and Medical Specialists for Septo-Optic Dysplasia

Rate This Website

What do you think about the features of this website? Take our user survey and have your say:

Website User Survey

Medical Tools & Articles:

Next articles:

Tools & Services:

Medical Articles:

Forums & Message Boards

 
HONcode We subscribe to the HONcode principles

By using this site you agree to our Terms of Use. Information provided on this site is for informational purposes only; it is not intended as a substitute for advice from your own medical team. The information on this site is not to be used for diagnosing or treating any health concerns you may have - please contact your physician or health care professional for all your medical needs. Please see our Terms of Use.

Home | Symptoms | Diseases | Diagnosis | Videos | Tools | Forum | About Us | Terms of Use | Privacy Policy | Site Map | Advertise